Shares of POET Technologies slid 8.2% to $13.05 on May 19, extending a brutal retreat from last week's euphoric highs. In a matter of days, the photonics chipmaker closed a $400 million capital raise, watched its shares plunge by over a fifth, lost its chief financial officer, and saw multiple law firms file class-action lawsuits. The question now: is the selloff a healthy reset or a signal that the market got ahead of itself?
- A $50 Million Order Sparked a 43% Rally — Then Reality Set In
Key developments included partnerships with LITEON, Lessengers, and Lumilens, with a substantial purchase order from Lumilens worth $50 million.
That relationship is structured to potentially exceed $500 million in cumulative purchases over five years. But fulfilment of the purchase orders is subject to successful development and qualification of the modules, as well as scaling of manufacturing capability, with engineering samples not expected until late 2026 and production ramp in 2027. In other words, no meaningful revenue arrives for at least a year.
- $503,000 in Revenue vs. a Multi-Billion-Dollar Market Cap
POET reported Q1 2026 revenue of $503,389, up from $166,760 a year earlier, and a net loss of $12.3 million.
The company has a market capitalization around $2.2 billion with just $1.07 million in trailing twelve-month revenue. That price-to-sales ratio exceeds 900x — a level that demands near-flawless execution. The median analyst price target sits at just $8.20, with a high of $8.40 , implying the stock is priced roughly 60% above even the most optimistic Wall Street estimate.
- A $400 Million Dilution Bomb Hit at the Worst Moment
On May 15, POET announced a direct offering of 19,047,620 common shares plus matching warrants at a combined $21.00 per unit, raising $400 million.
The issuance creates immediate dilution, with an additional 19 million shares potentially hitting the market if the three-year warrant is fully exercised. That cash funds manufacturing scale-up, but traders reacted to the near-term dilution and added share supply.
- Cancelled Orders and Lawsuits Cloud the Narrative
The Lumilens momentum is overshadowed by the abrupt cancellation of all orders from Celestial AI — now part of Marvell — which cited alleged breaches of confidentiality, the same issue driving newly filed class-action complaints. For shareholders, the legal risk adds a wild card that no partnership announcement can offset until resolved.
The bottom line: POET has real technology and a genuine shot at the AI-infrastructure boom. But with negligible revenue, massive dilution, active litigation, and a stock trading leagues beyond analyst targets, the gap between promise and proof remains dangerously wide.